Bristol-Myers Squibb (NY:BMY)

58.81 -2.34 (-3.83%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

93 94 Next >

Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip ↗

February 06, 2025

The company announced plans to generate $2 billion in annual cost savings by the end of 2027.

Via Stocktwits

Wondering what's happening in today's S&P500 pre-market session? ↗

February 06, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts ↗

February 06, 2025

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans.

Via Benzinga

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. ↗

February 06, 2025

Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.

Via Investor's Business Daily

Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations

February 06, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s...

Via StockStory

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings) ↗

January 28, 2025

Via Benzinga

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

February 06, 2025

From Bristol Myers Squibb

Via Business Wire

US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst ↗

February 06, 2025

U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports.

Via Benzinga

Topics World Trade

Dow Rises Over 300 Points As Nvidia Surges: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗

February 06, 2025

Via Benzinga

Topics Stocks

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗

January 10, 2025

Via Benzinga

Bristol-Myers Squibb, Amazon And 3 Stocks To Watch Heading Into Thursday ↗

February 06, 2025

Via Benzinga

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow

February 05, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know.

Via StockStory

McDonald's To $290? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 04, 2025

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

February 04, 2025

Via Benzinga

Can Biotech Stocks Survive The Precarious Macro? ↗

February 03, 2025

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

Via Talk Markets

Topics Stocks / Equities World Trade

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond ↗

February 03, 2025

Via The Motley Fool

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Via Benzinga

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

January 31, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

January 31, 2025

From Bristol Myers Squibb

Via Business Wire

3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average ↗

January 29, 2025

Via The Motley Fool

Topics Stocks

Biotech And Healthcare Stocks Poised For Gains Ahead ↗

January 27, 2025

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

Via Talk Markets

Topics ETFs Stocks / Equities

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

January 25, 2025

From Bristol Myers Squibb

Via Business Wire

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗

January 13, 2025

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

Via Benzinga

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

January 13, 2025

From Arsenal Biosciences

Via GlobeNewswire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.